GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>if ATryn is granted priority review, I assume would we hear about it prior to the late July submission?<

No—the normal time for the FDA to rule on priority review is 45-60 days after a BLA/NDA submission. In this case, there’s little reason to think that GTC won’t get a priority review.